Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
November 6, 2014
Professor LJ Wei holds that rules are for lawyers, not (necessarily) clinicians. When designing modern clinical trials,...
Read article
October 28, 2014
Adaptive Dose Finding Using Toxicity Probability Intervals
Phase 1 oncology trials typically use either rule-based methods or model-based methods to determine the most acceptable...
Read article
October 21, 2014
Clinical Impact Beyond 'Time to First' Analyses
Every year, the East Users Group Meeting brings together notable experts from industry and academia to discuss the...
Read article
September 25, 2014
Part II: The Philosophy Behind a Software Package
A few weeks ago, we posted a synopsis of an event held at ISCB Vienna in which statisticians from Cytel, SAS and Stata...
Read article
August 26, 2014
Statisticians from Cytel, SAS and Stata talk Software Development
During an invited speakers session at the lnternational Society for Clinical Biostatistics, Cytel VP Yannis Jemiai was...
Read article
August 12, 2014
What Horsepower Can Teach us about Well-Powered Trials
Beyond Wild Horses: Developing Innovation at Cytel "Horse-and-pony" by arjecahn on flickr. -...
Read article
May 5, 2014
The Perils of Poor Recruitment
A new JAMA study on discontinued randomized trials in Switzerland, Germany and Canada, reports that poor recruitment...
Read article